Drug Profile


Alternative Names: Altosone; Asmanex Twisthaler; Ecotone; Ecural; Elica; Elocon; Fulmeta; Mometasone furoate monohydrate; Nasonex; Novasone; Rinelon; Rivelon; SCH 32088; Uniclar

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnadienediols; Skin disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Nasal polyps; Perennial allergic rhinitis; Seasonal allergic rhinitis; Sinusitis; Skin disorders
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for mometasone (Asmanex®) in Europe and Japan (Merck Annual report 2016)
  • 15 Sep 2016 MSD and Kyorin agree to co-promote Nasonex® in Allergic rhinitis in Japan
  • 17 Mar 2016 Efficacy and adverse events data from a phase II trial in Asthma presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAA1-2016 (3176428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top